Clinical Trials in Nashville

Showing 1361-1380 of 17,403 trials

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

NCT05254314

This is a randomized placebo-controlled trial of semaglutide, an FDA-approved therapy for the treatment of type 2 diabetes mellitus and obesity, in adults with symptomatic asthma despite the use of inhaled steroids and with excess body weight. This study will test the central hypothesis that semaglutide will improve asthma control and reduce airway inflammation due to direct effects on the respiratory tract in adult asthma associated with obesity.

Asthma

Vanderbilt University Medical Center100 participantsStarted Oct 2022

Nashville, Tennessee, United States

RECRUITINGPhase 2< 1 mile

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177

The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.

Opioid Use DisorderOpioid Use Disorder, ModerateOpioid Use Disorder, Severe

T. John Winhusen, PhD310 participantsStarted Dec 2025

Tarzana, California, United States • Jacksonville, Florida, United States • Tampa, Florida, United States +7 more locations

Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Find Trials by Condition in Nashville

Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Impella ECP Study (ECP Study) and Impella ECP Continued Access Protocol

Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Implementation of Whole Genome Sequencing as Screening in a Diverse Cohort of Healthy Infants

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

Lumason® Infusion vs. Bolus Administrations

Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

Trifecta-Lung cfDNA-MMDx Study

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

Post-sleeve Gastrectomy Gastroesophageal Reflux Disease Prediction